DS
ORKA

David Shaw’s Oruka Therapeutics ORKA Stock Holding History

David Shaw’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-76,415
Closed -$2.32M – 5164
2025
Q4 		$2.32M Sell
76,415
-19,002
-20% -$529K ﹤0.01% 2934
2025
Q3 		$1.83M Buy
95,417
+27,772
+41% +$412K ﹤0.01% 3043
2025
Q2 		$758K Buy
+67,645
New +$705K ﹤0.01% 3420

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

David Shaw's ORKA Position: Q1 2026 in Review

David Shaw sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 76,415 shares — an estimated $2.32M sold.

David Shaw first reported a position in ORKA in Q2 2025 and held it in 3 quarters. The position peaked at $2.32M in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • David Shaw reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • David Shaw sold 76,415 Oruka Therapeutics shares in Q1 2026, an estimated $2.32M.
  • David Shaw first reported a position in Oruka Therapeutics in Q2 2025 and held it in 3 quarters.
  • David Shaw's Oruka Therapeutics position peaked at $2.32M in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.